APOE and Alzheimer disease: The progression model was developed based on the Amyloid biomarker in PET scans and APOE4 in preclinical research and estimated Alzheimer’s Disease Assessment Scale-Cognitive Subscale 13 (ADAS-cog 13) scores [70].